Skip to main content

Grace Therapeutics, Inc.

GRCE
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
SEC CIK
0001444192

In the last 90 days, Grace Therapeutics, Inc. insiders filed 5 open-market purchases and 0 sales; 33 institutions reported holding it in 13F filings for Q2 2026, worth $8.74M in total; no superinvestor holds it.

Q3 2025 vs. Q2 2025

How the institutions holding Grace Therapeutics, Inc. changed between Q2 2025 and Q3 2025.

All holders in Q3 2025All holders in Q2 2025

13F holders of GRCE: Q2 2025 compared with Q3 2025
MeasureQ2 2025Q3 2025Change
Holders20200
Shares3.82M3.71M−110.7K (−2.9%)
Value$11.3M$11.0M−$311.1K (−2.7%)

New holders (2)

Institutions that held Grace Therapeutics, Inc. at the end of Q3 2025 but not at the end of Q2 2025.

Institutions new to GRCE in Q3 2025
InstitutionSharesValue% of portfolio
SeaCrest Wealth Management, LLC14,000$42.0K0.00%
NBC Securities, Inc.2$50.00%

Sold out (2)

Institutions that held Grace Therapeutics, Inc. at the end of Q2 2025 and filed for Q3 2025 without it.

Institutions that sold out of GRCE in Q3 2025
InstitutionShares, Q2 2025Value, Q2 2025
Palumbo Wealth Management LLC48,541$144.2K
Jones Financial Companies LLLP29$86